ZS Pharma
Develops ion trap therapies for the treatment of life-threatening medical conditions such as hyperkalemia and liver diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
$2.7b | Acquisition | ||
| Total Funding | 000k | ||
Related Content
ZS Pharma, a subsidiary of AstraZeneca, specializes in developing and commercializing innovative treatments for hyperkalemia, a condition characterized by elevated potassium levels in the blood. The company primarily serves healthcare providers and patients in the pharmaceutical market. ZS Pharma's core product, Lokelma, is designed to treat hyperkalemia by binding potassium in the gastrointestinal tract, thereby reducing its absorption into the bloodstream. The business model focuses on research and development, regulatory approval, and commercialization of pharmaceutical products. Revenue is generated through product sales, partnerships, and licensing agreements. ZS Pharma operates in a highly regulated market, ensuring compliance with stringent healthcare standards and data privacy obligations.
Keywords: hyperkalemia, Lokelma, pharmaceutical, healthcare, potassium, gastrointestinal, treatment, innovation, compliance, AstraZeneca.